...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Combined effects of interleukin-7 and stem cell factor administration on lymphopoiesis after murine bone marrow transplantation.
【24h】

Combined effects of interleukin-7 and stem cell factor administration on lymphopoiesis after murine bone marrow transplantation.

机译:白细胞介素7和干细胞因子给药对小鼠骨髓移植后淋巴细胞生成的联合作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The decreased ability of the thymus to generate T cells after bone marrow transplantation (BMT) is a clinically significant problem. Interleukin (IL)-7 and stem cell factor (SCF) induce proliferation, differentiation, and survival of thymocytes. Although previous studies have shown that administration of recombinant human IL-7 (rhIL-7) after murine and human BMT improves thymopoiesis and immune function, whether administration of SCF exerts similar effects is unclear. To evaluate independent or combinatorial effects of IL-7 and SCF in post-BMT thymopoiesis, bone marrow (BM)-derived mesenchymal stem cells transduced ex vivo with the rhIL-7 or murine SCF (mSCF) genes were cotransplanted with T cell-depleted BM cells into lethally irradiated mice. Although rhIL-7 and mSCF each improved immune reconstitution, the combination treatment had a significantly greater effect than either cytokine alone. Moreover, the combination treatment significantly increased donor-derived common lymphoid progenitors (CLPs) in BM, suggesting that transplanted CLPs expand more rapidly in response to IL-7 and SCF and may promote immune reconstitution. Our findings demonstrate that IL-7 and SCF might be therapeutically useful for enhancing de novo T cell development. Furthermore, combination therapy may allow the administration of lower doses of IL-7, thereby decreasing the likelihood of IL-7-mediated expansion of mature T cells.
机译:骨髓移植(BMT)后胸腺产生T细胞的能力下降是临床上的重大问题。白介素(IL)-7和干细胞因子(SCF)诱导胸腺细胞增殖,分化和存活。尽管先前的研究表明,在鼠和人BMT后施用重组人IL-7(rhIL-7)可以改善胸腺生成和免疫功能,但尚不清楚SCF的施用是否发挥类似作用。为了评估IL-7和SCF在BMT后的胸腺造血中的独立或组合作用,将与rhIL-7或鼠SCF(mSCF)基因离体转导的骨髓(BM)来源的间充质干细胞与贫T细胞共移植BM细胞进入经致死性照射的小鼠体内。尽管rhIL-7和mSCF均改善了免疫重建,但联合治疗比单独使用任何一种细胞因子的效果明显更好。此外,联合治疗显着增加了BM中供体来源的常见淋巴祖细胞(CLP),这表明移植的CLP对IL-7和SCF的反应更迅速地扩增,并可能促进免疫重建。我们的发现表明,IL-7和SCF对增强新生T细胞发育可能具有治疗作用。此外,联合疗法可允许给予较低剂量的IL-7,从而降低了IL-7介导的成熟T细胞扩增的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号